[Special Stock] Caregen Shows Strong Performance for Two Consecutive Days Following Report Forecasting 40% Sales Growth Over 3 Years

Caregen is showing strong performance. This is interpreted as being influenced by a report from Nomura Securities stating that Caregen is expected to achieve an average annual sales growth of over 40% for the next three years.

As of 9:59 AM on the 13th, Caregen is trading at 234,000 KRW, up 2.86% compared to the previous day.

According to a media outlet, on the 11th (local time), Kara Song, a researcher at Nomura Securities, analyzed Caregen, stating that "with strong new product momentum, it is possible to achieve an average annual sales growth rate of over 40% and an operating profit margin (OPM) of over 60% for the next three years."

Caregen produces and sells cosmetics and medical device products based on research and technology related to peptides. Peptides can be developed into health functional foods and pharmaceuticals; the food products are at the commercialization stage, and pharmaceuticals are at the prototype stage of research. Additionally, Caregen has signed an exclusive supply contract with the global chemical company BASF for four patented peptide raw materials.

This content was produced with the assistance of AI translation services.